Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4887137 | 0.83 | HTR1A (0.38) | HTR1ADRD2DRD4HTR2AHTR2C | |
| SCHEMBL4163673 | 0.75 | ACHE (0.42) | ALDH1A1MAPT | |
| SCHEMBL4882602 | 0.75 | DRD2 (0.43) | HTR1ADRD2DRD4HTR2AHTR2C | |
| SCHEMBL22333200 | 0.72 | ALDH1A1 (0.43) | HTR1ADRD2DRD4HTR2AHTR2C | |
| SCHEMBL27811798 | 0.71 | NCF1 (0.51) | HTR1ADRD2DRD4HTR2AHTR2C | |
| SCHEMBL4889066 | 0.70 | HTR7 (0.44) | HTR1ADRD2HTR2AHTR2CMAPT | |
| SCHEMBL5547464 | 0.70 | SLC6A7 (0.34) | HTR1ADRD2DRD4DRD3HTR1D | |
| SCHEMBL4888363 | 0.69 | HTR6 (0.61) | HRH4 | |
| SCHEMBL22333183 | 0.69 | HRH4 (0.42) | HTR1ADRD2DRD4HTR2AHTR2C | |
| SCHEMBL5549018 | 0.65 | NCF1 (0.39) | HTR1ADRD2HTR2AHTR2CHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045537-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-02-21 | — | — | US | disclosed |
| EP-1789045-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006023400-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045537-A1 | Chemical Compounds | CCR5, CXCR4, CXCR3 | HTR1A 3730/4885DRD2 894/4885DRD4 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.